Nonfunctioning XXXX of the pancreas.

@entity1 @entity788 @entity5 @entity189 @entity3508 @entity490 @entity1943
The clinical features of eight @entity1 and three @entity1 with nonfunctioning islet cell @entity788 were reviewed. The mean @entity1 age was 58 years (range 44 to 75 years). Weight loss and @entity490 were the most frequent presenting symptoms. An abdominal mass was palpable in five @entity1 . At operation regional or distant metastases were present in 82% of @entity1 . Only 18% of @entity1 underwent resection for potential cure. All @entity5 proved histologically to be neuroendocrine in origin. Immunohistochemical staining showed positive reactivity for @entity3508 and chromogranin in all @entity5 studied but was negative for insulin, glucagon, and @entity1943 . Focal positivity for pancreatic polypeptide was seen in one @entity5 . Nine @entity1 with unresectable disease at operation were available for follow-up. Mean survival for the entire group was 23 +/- 7.2 months (range 4 to 72 months). Survival differences between @entity1 and @entity1 appeared to favor @entity1 but were not statistically significant. Postoperative regional or systemic chemotherapy also had no significant effect on @entity1 survival although two of the longest survivors (36 and 72 months) had received adjunctive chemotherapy. Nonfunctioning islet cell @entity5 are locally aggressive, have a propensity for early metastases, and are rarely resectable for cure. Unlike pancreatic exocrine @entity189 , endocrine @entity5 may respond favorably to adjunctive chemotherapy.
